- Conditions
- Menorrhagia, Uterine Fibroids
- Interventions
- Doppler-Guided Uterine Artery Occlusion Device (DUAO)
- Device
- Lead sponsor
- Ethicon, Inc.
- Industry
- Eligibility
- 25 Years to 50 Years · Female only
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Fort Lauderdale, Florida • Southfield, Michigan + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Uterine Fibroids
- Interventions
- Vilaprisan (BAY1002670), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Arcadia, California • Cerritos, California + 43 more
- Conditions
- Uterine Fibroid, Endometriosis
- Interventions
- Not listed
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 660 participants
- Timeline
- 2018 – 2020
- U.S. locations
- 37
- States / cities
- Mobile, Alabama • Mesa, Arizona • Huntington Beach, California + 31 more
- Conditions
- Menorrhagia, Heavy Menstrual Bleeding
- Interventions
- Tranexamic acid tablets, Placebo tablets
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
- Interventions
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 0 Years to 20 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
- Conditions
- Uterine Leiomyoma, Uterine Fibroids
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Placebo for relugolix, Placebo for E2/NETA
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroid
- Interventions
- Relugolix, Estradiol/norethindrone acetate
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 104
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Mobile, Alabama + 84 more
- Conditions
- Metrorrhagia, Pelvic Pain, Menorrhagia, Leiomyoma
- Interventions
- Myfembree Oral Product
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Flossmoor, Illinois • Orland Park, Illinois + 1 more
- Conditions
- Iron Deficiency Anemia Treatment, Iron Deficiency, Iron Deficiency (Without Anemia)
- Interventions
- FeoSol Original Iron Supplement Tablets, 21st Century Gelatin Capsules
- Dietary Supplement
- Lead sponsor
- Purdue University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- West Lafayette, Indiana
- Conditions
- Laparoscopic Myomectomy
- Interventions
- Not listed
- Lead sponsor
- The Advanced Gynecologic Surgery Institute
- Other
- Eligibility
- 16 Years to 70 Years · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Naperville, Illinois
- Conditions
- Heavy Menstrual Bleeding, Menorrhagia, Uterine Fibroids
- Interventions
- Levonorgestrel IUS, Tranexamic Acid
- Drug
- Lead sponsor
- Shannon K. Laughlin-Tommaso
- Other
- Eligibility
- 25 Years to 50 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Climacteric; Menorrhagia, Menopausal, Menopause
- Interventions
- 50 mg PYC and then placebo, 100 mg PYC and then placebo, Placebo and then 50 mg PYC, Placebo and then 100 mg PYC
- Dietary Supplement
- Lead sponsor
- Legacy Health System
- Other
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 3
- States / cities
- Gresham, Oregon • Portland, Oregon • Tualatin, Oregon
- Conditions
- Menorrhagia
- Interventions
- Naproxen, Placebo
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Seattle, Washington
- Conditions
- Von Willebrand Disease, Type 1, Heavy Menstrual Bleeding
- Interventions
- Volta System
- Device
- Lead sponsor
- Five Liters, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Heavy Menstrual Bleeding
- Interventions
- Volta System
- Device
- Lead sponsor
- Spark Biomedical, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Contraception
- Interventions
- Levonorgestrel IUS (Mirena, BAY86-5028)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 49
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 44 more
- Conditions
- Von Willebrand Factor Deficiency
- Interventions
- Genetic Analysis, Medical Record Data Abstraction, Pictorial Blood Assessment Chart (PBAC) score, Complete Bleeding Symptom ISTH Bleeding Assessment Tool
- Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 21 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 12
- States / cities
- Atlanta, Georgia • East Lansing, Michigan • Kansas City, Missouri + 9 more
- Conditions
- Symptomatic Uterine Fibroids
- Interventions
- Global Fibroid Ablation (GFA), Abdominal or Laparoscopic Myomectomy, Uterine Artery Embolization (UAE)
- Procedure
- Lead sponsor
- Acessa Health, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 9
- States / cities
- Santa Monica, California • Walnut Creek, California • Augusta, Georgia + 6 more
- Conditions
- Uterine Fibroids, Menorrhagia, Endometriosis
- Interventions
- conventional laparoscopic hysterectomy, robotic assisted laparoscopic hysterectomy
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Menorrhagia
- Interventions
- tranexamic acid
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 16 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Menorrhagia
- Interventions
- NovaSure Endometrial Ablation
- Device
- Lead sponsor
- Hologic, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 14
- States / cities
- Chandler, Arizona • Arvada, Colorado • Sarasota, Florida + 11 more
- Conditions
- Abnormal Uterine Bleeding, Abnormal Uterine Bleeding, Ovulatory Dysfunction, Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
- Interventions
- Levonorgestrel intrauterine system, Combined oral contraceptives
- Device · Drug
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Anemia
- Interventions
- Ferric Carboxymaltose (FCM), Ferrous Sulfate tablets
- Drug
- Lead sponsor
- American Regent, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Norristown, Pennsylvania
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroid
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more